Department of Chemistry and Chemical Biology, McMaster University, Hamilton, Ontario, L8S 4M1, Canada.
LifeMine Therapeutics, Cambridge, Massachusetts, 02140, USA.
Sci Rep. 2020 Mar 12;10(1):4599. doi: 10.1038/s41598-020-61088-x.
Fungal endophytes are sources of novel bioactive compounds but relatively few agriculturally important fruiting plants harboring endophytes have been carefully studied. Previously, we identified a griseofulvin-producing Xylaria species isolated from Vaccinium angustifolium, V. corymbosum, and Pinus strobus. Morphological and genomic analysis determined that it was a new species, described here as Xylaria ellisii. Untargeted high-resolution LC-MS metabolomic analysis of the extracted filtrates and mycelium from 15 blueberry isolates of this endophyte revealed differences in their metabolite profiles. Toxicity screening of the extracts showed that bioactivity was not linked to production of griseofulvin, indicating this species was making additional bioactive compounds. Multivariate statistical analysis of LC-MS data was used to identify key outlier features in the spectra. This allowed potentially new compounds to be targeted for isolation and characterization. This approach resulted in the discovery of eight new proline-containing cyclic nonribosomal peptides, which we have given the trivial names ellisiiamides A-H. Three of these peptides were purified and their structures elucidated by one and two-dimensional nuclear magnetic resonance spectroscopy (1D and 2D NMR) and high-resolution tandem mass spectrometry (HRMS/MS) analysis. The remaining five new compounds were identified and annotated by high-resolution mass spectrometry. Ellisiiamide A demonstrated Gram-negative activity against Escherichia coli BW25113, which is the first reported for this scaffold. Additionally, several known natural products including griseofulvin, dechlorogriseofulvin, epoxy/cytochalasin D, zygosporin E, hirsutatin A, cyclic pentapeptides #1-2 and xylariotide A were also characterized from this species.
真菌内生菌是新型生物活性化合物的来源,但相对较少对具有内生菌的农业上重要的结果植物进行了仔细研究。此前,我们从 Vaccinium angustifolium、V. corymbosum 和 Pinus strobus 中分离到一株产生灰黄霉素的 Xylaria 物种,并对其进行了鉴定。形态学和基因组分析确定它是一个新物种,现描述为 Xylaria ellisii。对该内生真菌的 15 个蓝莓分离物的提取滤液和菌丝体进行非靶向高分辨率 LC-MS 代谢组学分析,揭示了它们代谢谱的差异。提取物的毒性筛选表明生物活性与灰黄霉素的产生无关,这表明该物种正在产生其他生物活性化合物。对 LC-MS 数据进行多元统计分析,以确定谱图中的关键异常特征。这允许针对分离和表征潜在的新化合物。这种方法导致发现了八种新的脯氨酸环状非核糖体肽,我们将其命名为 ellisiiamides A-H。其中三种肽被纯化,并通过一维和二维核磁共振波谱(1D 和 2D NMR)和高分辨率串联质谱(HRMS/MS)分析确定了其结构。其余五个新化合物通过高分辨率质谱进行了鉴定和注释。Ellisiiamide A 对革兰氏阴性菌 Escherichia coli BW25113 表现出活性,这是该支架的首次报道。此外,还从该物种中鉴定和注释了几种已知的天然产物,包括灰黄霉素、脱氯灰黄霉素、环氧/细胞松弛素 D、zygosporin E、hirsutatin A、环状五肽 #1-2 和 xylariotide A。